Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Positive data, toxicity, a US FDA delay and the early leaking of information culminate in a green light for the multiple myeloma drug.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.